Oregon Biotech Company Receives OK to Sell Shares
BEAVERTON, Ore. — Epitope Inc. announced that the Securities and Exchange Commission has approved its sale of 1.25 million shares of common stock at $5 each.
Shares in the biotechnology company are being sold to a limited number of U.S. and European institutional and other qualified investors, officials said. Sutro & Co. of San Francisco is the underwriter for the stock offering.
Net proceeds from the offering will be used in development of new diagnostic tests for AIDS, therapeutic drugs for malaria, antiviral barriers and novel plant varieties, as well as general corporate purposes, Epitope officials said.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
